Alpha-lipoic acid (ALA) is a naturally occurring compound that functions as a cofactor for several mitochondrial enzyme complexes involved in energy metabolism — including pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase. Unlike most antioxidants, which are either water-soluble (like vitamin C) or fat-soluble (like vitamin E), ALA is soluble in both environments. This dual solubility allows it to act as an antioxidant in aqueous cellular cytoplasm and in lipid-rich cell membranes — which is why it is sometimes called the "universal antioxidant."
R-ALA vs S-ALA: the isomer distinction
Alpha-lipoic acid exists as two mirror-image isomers: R-alpha-lipoic acid (R-ALA) and S-alpha-lipoic acid (S-ALA). The R form is the naturally occurring biological isomer — the form produced by the body and found in food (where ALA is protein-bound). The S form is produced synthetically during chemical manufacturing. Most commercial ALA supplements are racemic mixtures (50% R, 50% S), though R-ALA-only supplements are available at premium prices.
Research suggests R-ALA is more bioactive — it is more efficiently absorbed and more readily recycled back to its active form after being oxidised. S-ALA may also interfere with some of R-ALA's enzymatic functions. However, the clinical evidence base is built primarily on racemic ALA, so the practical difference for most users remains unclear.
Antioxidant network role
ALA's antioxidant activity extends beyond direct free radical scavenging. Notably, ALA can regenerate other antioxidants — including vitamins C and E, and glutathione — from their oxidised (spent) forms back to their active states. It also directly stimulates glutathione synthesis by increasing cellular cysteine uptake. This "antioxidant recycling" function is a distinguishing feature of ALA compared to single-mechanism antioxidants.
Clinical evidence
Diabetic neuropathy is the area with the strongest clinical evidence for ALA. A series of German clinical trials (ALADIN, SYDNEY, NATHAN) used intravenous ALA at 600 mg/day and showed significant reductions in neuropathic symptom scores. Oral ALA (600–1,800 mg/day) showed more modest but statistically significant symptom improvements in the SYDNEY 2 trial over 5 weeks. The European Federation of Neurological Societies (EFNS) guidelines include ALA as a treatment option for diabetic polyneuropathy.
For glucose metabolism, several meta-analyses show that oral ALA supplementation reduces fasting blood glucose and insulin resistance markers — an effect attributed to ALA's stimulation of GLUT4 translocation to cell membranes, increasing glucose uptake independently of insulin.
Alpha-lipoic acid in Lebanon
Supplements & More carries alpha-lipoic acid supplements from US brands, available with cash on delivery across Lebanon.